Verapamil
Verapamil is a calcium channel blocker. The US label read is for verapamil hydrochloride tablets and lists three groups of uses: angina (angina at rest, including vasospastic and unstable angina, and chronic stable angina); arrhythmias (control of ventricular rate in chronic atrial flutter or atrial fibrillation, in association with digitalis, and prophylaxis of repetitive paroxysmal supraventricular tachycardia); and hypertension, to lower blood pressure. No brand-name tablet label for the immediate-release product was found in openFDA, so this page rests on a generic manufacturer's label. Extended-release products and the injection have their own labels, which were not read.
Also called Verapamil hydrochloride
- Drug
- In this atlas
Overview
Technical summary
RxNorm ingredient 11170; UNII V3888OEY5R. The label names the substance as verapamil hydrochloride, so UNII V3888OEY5R is the UNII of the salt form and is a broad match. MeSH descriptor D014700 is Verapamil. Class: Calcium Channel Blocker (FDA established pharmacologic class, RxClass). The label read is the verapamil hydrochloride tablets, Actavis Pharma, Inc. label, effective 2024-01-30 in openFDA (application ANDA070995). Other verapamil labels in openFDA, from other sponsors and repackagers, were not read. This page records label indications and the class only: no trial result and no dose is given.
Trials at a glance
The figures count the 3 registry trials in this atlas that name this drug or a product that contains it. Trials that use another name for it are not counted.
- Trials
- 3
- Phase 3 or 4
- 2
- Recruiting
- 1
- Regulatory decisions
- 0
| Phase | Recruiting | Not yet recruiting | Active, not recruiting | All statuses |
|---|---|---|---|---|
| Phase 2 | 0 | 0 | 1 | 1 |
| Phase 4 | 1 | 1 | 0 | 2 |
| All phases | 1 | 1 | 1 | 3 |
Conditions these trials study
- Arrhythmia (heart rhythm problems)
- Atrial fibrillation (AF)
- Cardiomyopathy (heart muscle disease)
- Diabetes mellitus
- Hypertrophic cardiomyopathy
- Type 2 diabetes
Sponsors with the most trials
- Cambridge University Hospitals NHS Foundation Trust
- Morten Steen Kvistholm Jensen
- Muhammad Ali Javed
About this drug
- Level
- Substance
- Mechanism
- Not reported
Classification codes
-
V3888OEY5R
Claims and evidence
Context People for whom the US label of verapamil hydrochloride tablets lists an indication: angina, atrial flutter or fibrillation, supraventricular tachycardia, hypertension
- Recipient
- Recipient not specified
- Population
- Patients described in the indications section of the label. The label does not state an age range in the passages read.
- Care setting
- Prescription medicine, as described in the US label
- Geography
- United States (label of the US Food and Drug Administration)
- Life stage
- Not stated in the label passages read
- Gestational age
- Not reported
- Postnatal age
- Not reported
- Follow-up
- Not applicable (label statement)
Eligibility: 5 inclusion criteria; exclusion criteria not stated
- Included
- Patients with angina at rest, including vasospastic and unstable angina
- Patients with chronic stable angina
- Patients with chronic atrial flutter or atrial fibrillation needing ventricular rate control, in association with digitalis
- Patients needing prophylaxis of repetitive paroxysmal supraventricular tachycardia
- Patients with essential hypertension
- Excluded
- None stated
The US label of verapamil hydrochloride tablets, in the Actavis Pharma, Inc. version dated 2024-01-30 in openFDA, lists the medicine for angina (angina at rest, including vasospastic and unstable angina, and chronic stable angina); for arrhythmias (control of ventricular rate at rest and during stress, in association with digitalis, in patients with chronic atrial flutter or atrial fibrillation, and prophylaxis of repetitive paroxysmal supraventricular tachycardia); and for the treatment of hypertension, to lower blood pressure.
Applies to Recipient not specified People for whom the US label of verapamil hydrochloride tablets lists an indication: angina, atrial flutter or fibrillation, supraventricular tachycardia, hypertension
- Certainty method
- Not assessed
- Limitations
- This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked
- 2026-11-09
- Next evidence check due
- Not scheduled
Sources and citations (2)
-
- Locator
- results[0].indications_and_usage[0]
- How it applies
- The label sentences that give the indications named in the statement, each quoted in the research quote table.
- Retrieved
- Source effective date
- 2024-01-30
- Source state
- Current
- Version fingerprint
c29bed22ccec22e108dfe8ae23e8b2c021c7d8c27c14deb0f1c2bf7da2406a35- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20240130.
- Retrieved
- Source effective date
- 2024-01-30
- Source state
- Current
- Version fingerprint
c29bed22ccec22e108dfe8ae23e8b2c021c7d8c27c14deb0f1c2bf7da2406a35- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
FDA label
The FDA label of the application holder, as the openFDA label dataset holds it, for the products that contain this drug.
CALAN
No label from the application holder was found in the openFDA label dataset for application NDA018817. This page does not show another labeler's label in its place.
CALAN
No label from the application holder was found in the openFDA label dataset for application NDA019038. This page does not show another labeler's label in its place.
CALAN SR
No label from the application holder was found in the openFDA label dataset for application NDA019152. This page does not show another labeler's label in its place.
COVERA-HS
No label from the application holder was found in the openFDA label dataset for application NDA020552. This page does not show another labeler's label in its place.
ISOPTIN
No label from the application holder was found in the openFDA label dataset for application NDA018485. This page does not show another labeler's label in its place.
ISOPTIN
No label from the application holder was found in the openFDA label dataset for application NDA018593. This page does not show another labeler's label in its place.
TARKA
No label from the application holder was found in the openFDA label dataset for application NDA020591. This page does not show another labeler's label in its place.
VERAPAMIL HYDROCHLORIDE
No label from the application holder was found in the openFDA label dataset for application NDA018925. This page does not show another labeler's label in its place.
VERELAN
No label from the application holder was found in the openFDA label dataset for application NDA019614. This page does not show another labeler's label in its place.
VERELAN PM
No label from the application holder was found in the openFDA label dataset for application NDA020943. This page does not show another labeler's label in its place.
FDA decisions timeline
The regulatory decisions of the FDA that this atlas holds for this drug and the products that contain it, oldest first. Each links to its full record.
- Approval
NDA018485 - Approval
NDA018593 - Approval
NDA018925 - Approval
NDA019038 - Approval
NDA018817 - Supplemental approval
NDA018593 - Supplemental approval
NDA018593 - Supplemental approval
NDA018817 - Approval
NDA019152 - Supplemental approval
NDA018817 - Supplemental approval
NDA019152 - Approval
NDA019614 - Approval
NDA020552 - Approval
NDA020591 - Approval
NDA020943
Clinical links
Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.
-
Claim, not a settled fact FDA label lists hypertension as an indication: Hypertension (high blood pressure)
Applies to Recipient not specified People for whom the US label of verapamil hydrochloride tablets lists an indication: angina, atrial flutter or fibrillation, supraventricular tachycardia, hypertension
The US label of verapamil hydrochloride tablets, in the Actavis Pharma, Inc. version dated 2024-01-30 in openFDA, lists the medicine for angina (angina at rest, including vasospastic and unstable angina, and chronic stable angina); for arrhythmias (control of ventricular rate at rest and during stress, in association with digitalis, in patients with chronic atrial flutter or atrial fibrillation, and prophylaxis of repetitive paroxysmal supraventricular tachycardia); and for the treatment of hypertension, to lower blood pressure.Limitations. This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
-
Claim, not a settled fact FDA label lists chronic stable angina as an indication: Stable angina
Applies to Recipient not specified People for whom the US label of verapamil hydrochloride tablets lists an indication: angina, atrial flutter or fibrillation, supraventricular tachycardia, hypertension
The US label of verapamil hydrochloride tablets, in the Actavis Pharma, Inc. version dated 2024-01-30 in openFDA, lists the medicine for angina (angina at rest, including vasospastic and unstable angina, and chronic stable angina); for arrhythmias (control of ventricular rate at rest and during stress, in association with digitalis, in patients with chronic atrial flutter or atrial fibrillation, and prophylaxis of repetitive paroxysmal supraventricular tachycardia); and for the treatment of hypertension, to lower blood pressure.Limitations. This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
-
Claim, not a settled fact FDA label lists angina at rest, including unstable (crescendo, pre-infarction) angina, as an indication: Unstable angina
Applies to Recipient not specified People for whom the US label of verapamil hydrochloride tablets lists an indication: angina, atrial flutter or fibrillation, supraventricular tachycardia, hypertension
The US label of verapamil hydrochloride tablets, in the Actavis Pharma, Inc. version dated 2024-01-30 in openFDA, lists the medicine for angina (angina at rest, including vasospastic and unstable angina, and chronic stable angina); for arrhythmias (control of ventricular rate at rest and during stress, in association with digitalis, in patients with chronic atrial flutter or atrial fibrillation, and prophylaxis of repetitive paroxysmal supraventricular tachycardia); and for the treatment of hypertension, to lower blood pressure.Limitations. This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
-
Claim, not a settled fact FDA label lists ventricular rate control, in association with digitalis, in chronic atrial flutter or atrial fibrillation as an indication: Atrial fibrillation (AF)
Applies to Recipient not specified People for whom the US label of verapamil hydrochloride tablets lists an indication: angina, atrial flutter or fibrillation, supraventricular tachycardia, hypertension
The US label of verapamil hydrochloride tablets, in the Actavis Pharma, Inc. version dated 2024-01-30 in openFDA, lists the medicine for angina (angina at rest, including vasospastic and unstable angina, and chronic stable angina); for arrhythmias (control of ventricular rate at rest and during stress, in association with digitalis, in patients with chronic atrial flutter or atrial fibrillation, and prophylaxis of repetitive paroxysmal supraventricular tachycardia); and for the treatment of hypertension, to lower blood pressure.Limitations. This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
-
Claim, not a settled fact FDA label lists ventricular rate control, in association with digitalis, in chronic atrial flutter or atrial fibrillation as an indication: Atrial flutter
Applies to Recipient not specified People for whom the US label of verapamil hydrochloride tablets lists an indication: angina, atrial flutter or fibrillation, supraventricular tachycardia, hypertension
The US label of verapamil hydrochloride tablets, in the Actavis Pharma, Inc. version dated 2024-01-30 in openFDA, lists the medicine for angina (angina at rest, including vasospastic and unstable angina, and chronic stable angina); for arrhythmias (control of ventricular rate at rest and during stress, in association with digitalis, in patients with chronic atrial flutter or atrial fibrillation, and prophylaxis of repetitive paroxysmal supraventricular tachycardia); and for the treatment of hypertension, to lower blood pressure.Limitations. This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
-
Claim, not a settled fact FDA label lists prophylaxis of repetitive paroxysmal supraventricular tachycardia as an indication: Supraventricular tachycardia
Applies to Recipient not specified People for whom the US label of verapamil hydrochloride tablets lists an indication: angina, atrial flutter or fibrillation, supraventricular tachycardia, hypertension
The US label of verapamil hydrochloride tablets, in the Actavis Pharma, Inc. version dated 2024-01-30 in openFDA, lists the medicine for angina (angina at rest, including vasospastic and unstable angina, and chronic stable angina); for arrhythmias (control of ventricular rate at rest and during stress, in association with digitalis, in patients with chronic atrial flutter or atrial fibrillation, and prophylaxis of repetitive paroxysmal supraventricular tachycardia); and for the treatment of hypertension, to lower blood pressure.Limitations. This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
Registry records
Assembled by a program from ClinicalTrials.gov and openFDA. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.
Registry products 10
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 2 efficacy supplement approvals on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 2 efficacy supplement approvals on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 1 efficacy supplement approval on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.
Registry trials 3
Record details
- Record id
cardio:verapamil- Content hash
eabbf4dbac6a8c1ccf83fe9587ddc65a286941674d18cc961ef475e783500fe7